Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease ...

Why cutting back on salt is important—but going too low may disrupt blood pressure, electrolytes and overall health.

Mineralys (MLYS) is transitioning to a pre-commercial stage, supported by robust Phase 3 data and a strengthened cash position of $593.6 million.

Mineralys Therapeutics’ aldosterone synthase inhibitor has chalked up a third clinical win in recent months, demonstrating once again its potential to reduce blood pressure in patients with ...

Lorundrostat treatment led to greater reductions in 24-hour mean blood pressure compared with placebo in trial participants with uncontrolled and treatment-resistant hypertension. Lorundrostat, a ...

Therefore, we considered it of interest to test the hypothesis that the aldosterone antagonist canrenone can improve LV diastolic function in patients with essential hypertension. We planned a ...

With appropriate and ongoing treatment, most people with Addison’s disease can expect to lead active lives with a life expectancy similar to that of the general population. Addison’s disease, or ...

Addison’s disease occurs when the adrenal glands do not produce enough of two steroid hormones called cortisol and aldosterone. This can cause fatigue, weakness, digestion problems, dehydration, and ...

Credit: Getty Images Addison disease — also referred to as primary adrenal insufficiency — occurs when the adrenal glands do not produce enough cortisol and/or aldosterone. Addison disease occurs in 1 ...

Aldosterone has been described to initiate cardiovascular diseases by triggering exacerbated sterile vascular inflammation. The functions of CCL5 (C-C motif chemokine ligand 5) and its receptor CCR5 ...